Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background Immune checkpoint inhibitors (ICIs) have been increasingly used in cancer treatment, and a subset of patients undergo pseudoprogression. Recognizing the incidence of pseudoprogression is critical for clinical practice. Purpose To evaluate by systematic review and meta-analysis the incidence of pseudoprogression in cancer treatment with ICIs, and compare the incidence according to response criteria, tumor types, and immunotherapeutic agents. Materials and Methods Medline and Embase were searched to identify relevant studies published before December 31, 2018. Clinical trials, post hoc analysis of clinical trials, and prospective studies on ICI treatment in patients with malignant solid tumors were included. Pooled incidence of pseudoprogression for all included studies, per definition of pseudoprogression, cancer type, and drug type, was obtained by random-effects models with inverse variance weighting model. Results Seventeen studies with 3402 patients were analyzed. The pooled incidence of pseudoprogression was 6.0% (95% confidence interval: 5.0%, 7.0%). The definition of pseudoprogression were divided into four categories: progressive disease followed by partial response (PR) or complete response (CR) but not stable disease (SD) with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (six studies); progressive disease followed by SD or PR or CR with RECIST 1.1 (five studies); progressive disease followed by SD or PR or CR with RECIST 1.0 (three studies); and progressive disease followed by SD or PR or CR with immune-related response criteria (irRC) (three studies). Incidence of pseudoprogression varied from 4.5% to 8.0% per definition, ranged from 5.0% to 7.0% per cancer type, and was 5.6% with the monotherapy of programmed cell death-1 inhibitor. Conclusion The overall incidence of pseudoprogression was 6.0% and was less than 10% in subgroup analyses according to the definitions of pseudoprogression, cancer type, and immune checkpoint inhibitor type. Varying definitions across trials and studies indicates the need for uniform criteria of pseudoprogression for solid tumors. © RSNA, 2020 Online supplemental material is available for this article. See also the article by Dodd and MacDermott in this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the accumulating evidence of 'pseudoprogression' in a minority of ICB recipients 62”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222 · cited 5×
“There were eight clinical trials (13,14,22–26,28), five post hoc analyses of clinical trials (17,18,20,21,27), two subgroup analyses of clinical trials (15,16), one pooled analysis of clinical trials (2), and one post hoc analysis of a prospective cohort (19).”
BackgroundMethodInfluentialWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · cited 1×
“On the basis of the scientific evidence of higher reproducibility of the unidimensional approach compared with the bidimensional approach in irRC, the definition of pseudoprogression should be standardized to use a RECIST-based scheme (4,6).”
MethodTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved tests for a random effects meta‐regression with a single covariate
Knapp, G., & Hartung, J. (2003) · Statistics in Medicine · doi:10.1002/sim.1482 · Cited by 2,075
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Controlling the risk of spurious findings from meta-regression
Higgins, J. P. T., & Thompson, S. G. (2004) · Statistics in Medicine · doi:10.1002/sim.1752 · Cited by 1,267
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A., Marabelle, A., Soria, J.-C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,190
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Self-citationPseudoprogression and Immune-Related Response in Solid Tumors
Chiou, V. L., & Burotto, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6870 · Cited by 903
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Hodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522 · cited 2×
“Bidimensional measurements used in irRC and the World Health Organization response criteria have measurement variability (4) and higher misclassification rates for progressive disease compared with unidimensional measurements used in RECIST (40).”
MethodSelf-citationNovel patterns of response under immunotherapy
Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P., & Le Tourneau, C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 514 · cited 1×
“Immune checkpoint inhibitors (ICIs) that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been studied in clinical trials and applied in clinical practice (1).”
BackgroundErasmus, J. J., Gladish, G. W., Broemeling, L., Sabloff, B. S., Truong, M. T., Herbst, R. S., & Munden, R. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.144 · Cited by 476
Lee, J., Kim, K. W., Choi, S. H., Huh, J., & Park, S. H. (2015) · Korean Journal of Radiology · doi:10.3348/kjr.2015.16.6.1188 · Cited by 474
Self-citationMcDermott, D. F., Drake, C. G., Sznol, M., Choueiri, T. K., Powderly, J. D., Smith, D. C., Brahmer, J. R., Carvajal, R. D., Hammers, H. J., Puzanov, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1041 · Cited by 439
Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J. C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 349
Kim, K. W., Lee, J., Choi, S. H., Huh, J., & Park, S. H. (2015) · Korean Journal of Radiology · doi:10.3348/kjr.2015.16.6.1175 · Cited by 329
Self-citationLee, J. H., Long, G. V., Menzies, A. M., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R. F., Rizos, H., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5332 · Cited by 315
Escudier, B., Motzer, R. J., Sharma, P., Wagstaff, J., Plimack, E. R., Hammers, H. J., Donskov, F., Gurney, H., Sosman, J. A., Zalewski, P. G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.037 · Cited by 240
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Nishino, M., Hatabu, H., & Hodi, F. S. (2019) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 211 · cited 2×
“The reported incidence of pseudoprogression among patients treated with ICI was 10% or lower (5), ranging from 0.”
BackgroundResultSelf-citationGeorge, S., Motzer, R. J., Hammers, H. J., Redman, B. G., Kuzel, T. M., Tykodi, S. S., Plimack, E. R., Jiang, J., Waxman, I. M., & Rini, B. I. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0775 · Cited by 181
Long, G. V., Weber, J. S., Larkin, J., Atkinson, V., Grob, J.-J., Schadendorf, D., Dummer, R., Robert, C., Márquez-Rodas, I., McNeil, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1588 · Cited by 176
Nishino, M., Giobbie‐Hurder, A., Manos, M. P., Bailey, N., Buchbinder, E. I., Ott, P. A., Ramaiya, N. H., & Hodi, F. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0114 · Cited by 146
Self-citationRadiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
Katz, S. I., Hammer, M. M., Bagley, S. J., Aggarwal, C., Bauml, J. M., Thompson, J. C., Nachiappan, A. C., Simone, C. B., & Langer, C. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.010 · Cited by 114
Nishino, M., Dahlberg, S. E., Adeni, A. E., Lydon, C., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1434 · Cited by 91 · cited 2×
“These short time frames risk excluding patients with pseudoprogression too early from the immunotherapy (8,9,41).”
BackgroundResultSelf-citationNishino, M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0134-0 · Cited by 57 · cited 2×
“A subset of patients treated with ICI manifest an atypical pattern of tumor response either after an increase of tumor burden or appearance of new lesions, a phenomenon termed pseudoprogression, which is classified as progressive disease by conventional response criteria (2,3).”
BackgroundResultSelf-citationPseudoprogression and Measurement Variability
Nishino, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6759 · Cited by 14
Self-citation
Research works printed but not linked: 1
- 10. Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res 2017;23(16):4671-4679.
Cited by
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
“90,91 Longitudinal monitoring for emergent resistance mutations.”
A gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
“Given the accumulating evidence of ‘pseudoprogression’ in a minority of ICB recipients 62 , under the trial protocol, ICB therapy could extend beyond RECIST 1.1-defined PD if there was investigator-assessed clinical benefit and good participant tolerance of the study drugs until there was evidence…”
InfluentialImmune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, M., Scheiner, B., & Pinato, D. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00147-4 · Cited by 155
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Brastianos, P. K., Kim, A. E., Giobbie‐Hurder, A., Lee, E. Q., Wang, N., Eichler, A. F., Chukwueke, U. N., Forst, D. A., Arrillaga‐Romany, I., Dietrich, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29052-7 · Cited by 121
“This phenomenon has been described with solid tumors of diverse histologies, including meningioma, undergoing treatment with ICI 22,23 .”
Multiparametric MRI for characterization of the tumour microenvironment
Hoffmann, E., Masthoff, M., Kunz, W. G., Seidensticker, M., Bobe, S., Gerwing, M., Berdel, W. E., Schliemann, C., Faber, C., & Wildgruber, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00891-1 · Cited by 113
“These intratumoural changes can lead to an initial increase in lesion size, also known as pseudoprogression, followed by a partial or complete response 154 .”
Metadata
- Authors
- Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Radiology
- Published
- 2020-10
- Volume
- 297
- Issue
- 1
- Pages
- 87-96
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- PMC
- PMC7526949
- OpenAlex
- W3047211233
- Cited by
- 162
- References
- 45
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 22 · 2023: 31 · 2022: 27 · 2021: 19 · 2020: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Radiology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Research Foundation of Korea (2017R1A2B3011475)
- National Cancer Institute (R01CA203636)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pseudoprogression, immune checkpoint inhibitors, solid tumors, incidence, RECIST 1.1, immune-related response criteria, PD-1 inhibitors, tumor response assessment, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Neoplasms, Disease Progression, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.